<DOC>
	<DOC>NCT00283842</DOC>
	<brief_summary>The purpose of this study is to evaluate the safety and efficacy of DVS SR in the treatment of neuropathic pain associated with diabetic peripheral neuropathy.</brief_summary>
	<brief_title>Study Evaluating Desvenlafaxine Succinate Sustained-release (DVS SR) in Adult Outpatients With Pain Associated With Diabetic Peripheral Neuropathy</brief_title>
	<detailed_description />
	<mesh_term>Peripheral Nervous System Diseases</mesh_term>
	<mesh_term>Diabetic Neuropathies</mesh_term>
	<mesh_term>Desvenlafaxine Succinate</mesh_term>
	<criteria>Diabetes type 1 or 2 Painful symptoms of diabetic neuropathy in the lower extremities extremities for at least 6 months Major Depression Uncontrolled diabetes</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2011</verification_date>
	<keyword>neuropathic pain</keyword>
	<keyword>diabetic peripheral neuropathy</keyword>
</DOC>